Treatment-associated adverse events of grade 3 or higher included diarrhea (12%), alanine aminotransferase increase (8%), and increased aspartate aminotransferase (5%) with sotorasib, and neutropenia (9%), fatigue (6%), and febrile neutropenia (5%) with docetaxel5. This evidence concerns the gene GPT and neutropenia.